Analysts forecast that Kodiak Sciences Inc. (NYSE:KOD) will post earnings per share of ($0.44) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kodiak Sciences’ earnings, with estimates ranging from ($0.56) to ($0.31). The firm is expected to report its next earnings report on Thursday, June 27th.
According to Zacks, analysts expect that Kodiak Sciences will report full year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.24) to ($1.68). For the next financial year, analysts forecast that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.65) to ($1.66). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Kodiak Sciences.
Kodiak Sciences (NYSE:KOD) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.05.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at about $44,000. Deutsche Bank AG acquired a new stake in Kodiak Sciences in the 4th quarter valued at $87,000. Bank of New York Mellon Corp acquired a new stake in Kodiak Sciences in the 4th quarter valued at $94,000. Pura Vida Investments LLC acquired a new stake in Kodiak Sciences in the 4th quarter valued at $173,000. Finally, Geode Capital Management LLC bought a new position in shares of Kodiak Sciences in the 4th quarter valued at about $458,000.
Shares of NYSE:KOD traded down $0.08 during trading on Monday, reaching $6.98. The stock had a trading volume of 35,800 shares, compared to its average volume of 68,603. Kodiak Sciences has a 1-year low of $5.65 and a 1-year high of $11.10.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Featured Article: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.